BioCryst Pharmaceuticals
BCRX
302 hedge funds and large institutions have $2.37B invested in BioCryst Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 75 funds opening new positions, 115 increasing their positions, 76 reducing their positions, and 41 closing their positions.
134% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $6.09M
83% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 41
51% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 76
43% more capital invested
Capital invested by funds: $1.66B → $2.37B (+$716M)
11% more funds holding
Funds holding: 272 → 302 (+30)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.43% less ownership
Funds ownership: 100.82% → 99.39% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$85.6M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$37.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$33.2M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$32.1M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$31.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$28.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$22M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$16.9M |
| 4 |
Squarepoint
New York
|
-$12.6M |
| 5 |
Renaissance Technologies
New York
|
-$10.5M |
BCRX Hedge Fund Activity: Q1 2026 in Review
302 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2026, worth a combined $2.37B — up 43% from $1.66B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new BCRX positions and 41 closed out — a net gain of 34 holders — while 115 added to existing stakes and 76 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $85.6M. The largest seller was Kynam Capital Management, cutting an estimated $28.6M.
- 302 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2026, up from 272 in Q4 2025.
- Funds reported $2.37B of BioCryst Pharmaceuticals stock for Q1 2026, up 43% quarter-over-quarter.
- 75 funds opened new BioCryst Pharmaceuticals positions in Q1 2026 and 41 closed out, a net change of +34 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2026 was TCG Crossover Management, an estimated $85.6M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2026 was Kynam Capital Management, an estimated $28.6M sold.
Based on aggregated 13F filings for Q1 2026.